206561-63-9

Upstream product

• 3282-30-2 pivaloyl chloride 
• 206561-62-8 2-amino-7-methyl-3-phenylquinoxaline 
• 79249-40-4 2-chloro-7-methyl-2-phenylquinoxaline 

Downstream Products

• 206561-61-7 N-(7-Bromomethyl-3-phenyl-quinoxalin-2-yl)-2,2-dimethyl-propionamide 
• 206561-47-9 4-{[3-(2,2-Dimethyl-propionylamino)-2-phenyl-quinoxalin-6-ylmethyl]-amino}-benzoic acid ethyl ester 
• 206561-43-5 2,2-Dimethyl-N-{3-phenyl-7-[(3,4,5-trimethoxy-phenylamino)-methyl]-quinoxalin-2-yl}-propionamide 
• 206561-41-3 2,2-Dimethyl-N-(3-phenyl-7-{[prop-2-ynyl-(3,4,5-trimethoxy-phenyl)-amino]-methyl}-quinoxalin-2-yl)-propionamide 
• 206561-54-8 (S)-2-(4-{[3-(2,2-Dimethyl-propionylamino)-2-phenyl-quinoxalin-6-ylmethyl]-amino}-benzoylamino)-pentanedioic acid diethyl ester 

Relevant academic research and scientific papers

Quinoxaline chemistry: Part 9. Quinoxaline analogues of trimetrexate (TMQ) and 10-propargyl-5,8-dideazafolic acid (CB 3717) and its precursors. Synthesis and evaluation of in vitro anticancer activity

Eighteen quinoxalines bearing a methyleneanilino or methyleneaminobenzoylglutamate group on position 6 of the ring and various lipophilic substituents on positions 2 and 3 were prepared in order to discover if their structural analogy with both trimetrexate (TMQ) and 10-propargyl-5,8-dideazafolic acid (CB 3717) might display in vitro anticancer activity. Among these, 12 compounds were selected at the National Cancer Institute, Bethesda, MD, USA; they exhibited moderate (4b,d,i,l,m and 8) to strong (4f,h and 5a,e) cell-growth inhibition at a concentration of 10-4 M. Interesting selectivities were also recorded between 10-8 and 10-6 M. These analogues proved to be less potent inihibitors of tumor cells than other classical and non-classical antifolate analogues previously described by us.